[go: up one dir, main page]

PE20180317A1 - Anticuerpos anti-tau y metodos de uso - Google Patents

Anticuerpos anti-tau y metodos de uso

Info

Publication number
PE20180317A1
PE20180317A1 PE2017002517A PE2017002517A PE20180317A1 PE 20180317 A1 PE20180317 A1 PE 20180317A1 PE 2017002517 A PE2017002517 A PE 2017002517A PE 2017002517 A PE2017002517 A PE 2017002517A PE 20180317 A1 PE20180317 A1 PE 20180317A1
Authority
PE
Peru
Prior art keywords
hvr
seq
nos
sequence
amino acids
Prior art date
Application number
PE2017002517A
Other languages
English (en)
Inventor
Oskar Adolfsson
Gai Ayalon
Cara Danielle Marie Di
Isidro Hotzel
Original Assignee
Genentech Inc
Ac Immune Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc, Ac Immune Sa filed Critical Genentech Inc
Publication of PE20180317A1 publication Critical patent/PE20180317A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)

Abstract

Se refiere a un anticuerpos anti-Tau que comprende los HVRs seleccionados entre: (a) HVR-H1 que comprende las SEQ N°: 12, 22, 282, 292 y 342; HVR-H2 que comprende una secuencia de aminoacidos seleccionadas entre SEC ID Nos: 13, 23, 283, entre otros; (c) HVR-H3 que comprende una secuencia de aminoacidos seleccionadas entre SEC ID Nos: 14, 24, y 284 entre otros; (d) HVR-L1 que comprende una secuencia de aminoacidos seleccionadas entre SEC ID Nos: 15, 25, 285, entre otros; y HVR-L2 que comprende una secuencia de aminoacidos seleccionadas entre SEC ID Nos: 16, 26, 286, entre otros; y (f) HVR-L3 que comprende una secuencia de aminoacidos seleccionadas entre SEC ID Nos: 17, 27, 287, entre otros. Estos se usan como metodo para retener o aumentar la capacidad cognitiva o desaceleracion de memoria; entre otras.
PE2017002517A 2015-06-05 2016-06-02 Anticuerpos anti-tau y metodos de uso PE20180317A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562171693P 2015-06-05 2015-06-05

Publications (1)

Publication Number Publication Date
PE20180317A1 true PE20180317A1 (es) 2018-02-09

Family

ID=56118083

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2017002517A PE20180317A1 (es) 2015-06-05 2016-06-02 Anticuerpos anti-tau y metodos de uso

Country Status (29)

Country Link
US (5) US10112990B2 (es)
EP (2) EP3303386B1 (es)
JP (3) JP6793134B2 (es)
KR (1) KR102768863B1 (es)
CN (2) CN114057872A (es)
AR (1) AR104875A1 (es)
AU (2) AU2016270858B2 (es)
CA (2) CA2986942C (es)
CL (2) CL2017003063A1 (es)
CO (1) CO2018000046A2 (es)
CR (1) CR20180013A (es)
DK (1) DK3303386T3 (es)
ES (1) ES2991587T3 (es)
FI (1) FI3303386T3 (es)
IL (3) IL314569A (es)
MA (1) MA44955A (es)
MX (3) MX392257B (es)
NZ (2) NZ775762A (es)
PE (1) PE20180317A1 (es)
PH (2) PH12021551770A1 (es)
PL (1) PL3303386T3 (es)
PT (1) PT3303386T (es)
RU (1) RU2732122C2 (es)
SG (1) SG10201911349YA (es)
SI (1) SI3303386T1 (es)
TW (4) TWI827405B (es)
UA (1) UA126272C2 (es)
WO (1) WO2016196726A1 (es)
ZA (3) ZA201707644B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA035943B1 (ru) 2013-03-13 2020-09-03 Протена Биосайенсес Лимитед Антитело, связывающееся с тау-белком человека
LT3277321T (lt) 2015-04-01 2024-10-25 Anaptysbio, Inc. Antikūnai, nukreipti prieš t ląstelių imunoglobuliną ir mucino baltymą 3 (tim-3)
MX392257B (es) 2015-06-05 2025-03-24 Genentech Inc Anticuerpos anti-tau y metodos de uso
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
CN109415432B (zh) 2016-05-02 2022-07-08 普罗塞纳生物科学有限公司 Tau免疫疗法
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
KR20190098741A (ko) 2016-11-01 2019-08-22 아납티스바이오, 아이엔씨. T 세포 면역글로불린 및 뮤신 단백질 3(tim-3)에 대한 항체
EP3551655A2 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
CN118165104A (zh) * 2016-12-07 2024-06-11 基因泰克公司 抗tau抗体和使用方法
BR112019017021A2 (pt) 2017-02-17 2020-04-14 Denali Therapeutics Inc anticorpos anti-tau e métodos de uso dos mesmos
TWI848907B (zh) * 2017-03-28 2024-07-21 美商建南德克公司 治療神經退化性疾病之方法
PE20200695A1 (es) 2017-05-02 2020-06-16 Prothena Biosciences Ltd Anticuerpos que reconocen tau
CN110998329B (zh) * 2017-07-20 2024-06-25 西托姆克斯治疗公司 定性和/或定量分析可活化抗体的特性的方法及其用途
US10829547B2 (en) 2017-10-16 2020-11-10 Eisai R&D Management Co., Ltd. Anti-tau antibodies and uses thereof
IL273980B2 (en) 2017-10-25 2025-02-01 Janssen Pharmaceuticals Inc Phosphorylated tau peptide preparations and uses thereof
NL2020520B1 (en) * 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
EP3762414A4 (en) * 2018-03-05 2022-01-05 Janssen Pharmaceutica NV TESTS TO DETECT NEURODEGENERATION
CA3093200A1 (en) 2018-03-05 2019-09-12 Janssen Pharmaceutica Nv Anti-phf-tau antibodies and uses thereof
EA202092122A1 (ru) * 2018-03-08 2020-12-03 Фейнз Терапьютикс, Инк. Антитела против tip-1 и их применения
WO2020097155A1 (en) 2018-11-06 2020-05-14 Alsatech, Inc. Cell-based gene therapy for neurodegenerative diseases
MX2021005411A (es) * 2018-11-08 2021-07-06 Prothena Biosciences Ltd Anticuerpos que reconocen tau.
WO2020153940A1 (en) * 2019-01-22 2020-07-30 Clemson University Anti-elastin antibodies and methods of use
EP3883971A1 (en) * 2019-01-22 2021-09-29 The United States of America, as represented by the Secretary, Department of Health and Human Services High affinity monoclonal antibodies targeting glypican-1 and methods of use
US12365730B2 (en) * 2019-01-28 2025-07-22 Tuojie Biotech (Shanghai) Co., Ltd. Anti-CD79B antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
AU2020219804A1 (en) 2019-02-08 2021-08-19 Ac Immune S.A. Method of safe administration of phosphorylated Tau peptide vaccine
EP3921343A4 (en) * 2019-02-08 2022-12-14 Prothena Biosciences Limited ANTIBODIES FOR DETECTING TAU
CN119371527A (zh) 2019-03-03 2025-01-28 普罗塞纳生物科学有限公司 识别tau的抗体
CN114173812A (zh) 2019-04-24 2022-03-11 杨森制药公司 Tau疫苗的异源给予
CA3142040A1 (en) * 2019-05-27 2020-12-03 The University Of British Columbia Conformation-specific epitopes in tau, antibodies thereto and methods related thereof
JP7227895B2 (ja) * 2019-12-23 2023-02-22 株式会社堀場製作所 相互作用検出方法、相互作用検出装置及びバイオチップ再生キット
US20230391855A1 (en) * 2020-10-21 2023-12-07 La Jolla Institute For Immunology Chimeric anti-sars-cov2 nucleoprotein antibodies
CN113005096B (zh) * 2021-01-19 2022-10-14 华中科技大学 分泌抗丝氨酸磷酸化tau蛋白单克隆抗体的杂交瘤细胞株
IL310382A (en) * 2021-08-27 2024-03-01 Genentech Inc Methods for treating tau pathologies
CN118235043A (zh) * 2021-09-09 2024-06-21 阿尔茨帕斯公司 磷酸化-tau抗体和使用方法
KR20240134174A (ko) * 2022-01-12 2024-09-06 지틴벤트 리미티드 타액 샘플에서 타우(tau) 단백질을 검출하기 위한 방법
US20250355002A1 (en) * 2022-06-14 2025-11-20 The Johns Hopkins University Identification of tdp-43 cryptic exon-encoded neoepitopes as functional fluid biomarkers for alzheimer's disease and related dementia
AU2023342086A1 (en) 2022-09-15 2025-03-13 Voyager Therapeutics, Inc. Tau binding compounds
WO2025134068A1 (en) 2023-12-22 2025-06-26 Ac Immune Sa Antibody drug conjugates targeting proteinopathies, and uses thereof

Family Cites Families (132)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4737456A (en) 1985-05-09 1988-04-12 Syntex (U.S.A.) Inc. Reducing interference in ligand-receptor binding assays
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5811310A (en) 1986-09-30 1998-09-22 Albert Einstein College Of Medicine Of Yeshiva Univ. The Alz-50 monoclonal antibody and diagnostic assay for alzheimer's disease
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
AU634186B2 (en) 1988-11-11 1993-02-18 Medical Research Council Single domain ligands, receptors comprising said ligands, methods for their production, and use of said ligands and receptors
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US5208020A (en) 1989-10-25 1993-05-04 Immunogen Inc. Cytotoxic agents comprising maytansinoids and their therapeutic use
US5959177A (en) 1989-10-27 1999-09-28 The Scripps Research Institute Transgenic plants expressing assembled secretory antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU7121191A (en) * 1990-02-26 1991-10-10 Albert Einstein College Of Medicine Of Yeshiva University Diagnostic assay for alzheimer's disease
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
GB9114948D0 (en) 1991-07-11 1991-08-28 Pfizer Ltd Process for preparing sertraline intermediates
EP0604580A1 (en) 1991-09-19 1994-07-06 Genentech, Inc. EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
DE69334255D1 (de) 1992-02-06 2009-02-12 Novartis Vaccines & Diagnostic Marker für Krebs und biosynthetisches Bindeprotein dafür
PL174721B1 (pl) 1992-11-13 1998-09-30 Idec Pharma Corp Przeciwciało monoklonalne anty-CD20
EP0714409A1 (en) 1993-06-16 1996-06-05 Celltech Therapeutics Limited Antibodies
US5789199A (en) 1994-11-03 1998-08-04 Genentech, Inc. Process for bacterial production of polypeptides
US5840523A (en) 1995-03-01 1998-11-24 Genetech, Inc. Methods and compositions for secretion of heterologous polypeptides
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
GB9603256D0 (en) 1996-02-16 1996-04-17 Wellcome Found Antibodies
US6171586B1 (en) 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
CA2293829C (en) 1997-06-24 2011-06-14 Genentech, Inc. Methods and compositions for galactosylated glycoproteins
US6040498A (en) 1998-08-11 2000-03-21 North Caroline State University Genetically engineered duckweed
JP2001521909A (ja) 1997-10-31 2001-11-13 ジェネンテク・インコーポレイテッド 糖タンパク質グリコフォームを含む方法及び組成物
US6610833B1 (en) 1997-11-24 2003-08-26 The Institute For Human Genetics And Biochemistry Monoclonal human natural antibodies
CA2312208C (en) 1997-12-05 2011-01-25 The Scripps Research Institute Humanization of murine antibody
ES2292236T3 (es) 1998-04-02 2008-03-01 Genentech, Inc. Variantes de anticuerpos y sus fragmentos.
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
DK1071700T3 (da) 1998-04-20 2010-06-07 Glycart Biotechnology Ag Glykosylerings-modifikation af antistoffer til forbedring af antistofafhængig cellulær cytotoksicitet
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
CN1763097B (zh) 1999-01-15 2011-04-13 杰南技术公司 具有改变的效应功能的多肽变体
EP2278003B2 (en) 1999-04-09 2020-08-05 Kyowa Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
ATE303445T1 (de) 1999-10-04 2005-09-15 Medicago Inc Verfahren zur regulation der transkription von fremden genen in gegenwart von stickstoff
US7125978B1 (en) 1999-10-04 2006-10-24 Medicago Inc. Promoter for regulating expression of foreign genes
AU7950400A (en) 1999-10-19 2001-04-30 Kyowa Hakko Kogyo Co. Ltd. Process for producing polypeptide
CA2393869A1 (en) 1999-12-15 2001-06-21 Genetech,Inc. Shotgun scanning, a combinatorial method for mapping functional protein epitopes
LT2857516T (lt) 2000-04-11 2017-09-11 Genentech, Inc. Multivalentiniai antikūnai ir jų panaudojimas
US7064191B2 (en) 2000-10-06 2006-06-20 Kyowa Hakko Kogyo Co., Ltd. Process for purifying antibody
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
ES2620359T3 (es) 2000-10-06 2017-06-28 Kyowa Hakko Kirin Co., Ltd. Células que producen unas composiciones de anticuerpo
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
EP1354034B8 (en) 2000-11-30 2008-06-18 Medarex, Inc. Transgenic transchromosomal rodents for making human antibodies
JP4336498B2 (ja) * 2000-12-12 2009-09-30 メディミューン，エルエルシー 延長した半減期を有する分子ならびにその組成物および用途
AT500379B8 (de) * 2001-02-02 2009-08-15 Axon Neuroscience Tau-proteine
NZ571596A (en) 2001-08-03 2010-11-26 Glycart Biotechnology Ag Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
DK1443961T3 (da) 2001-10-25 2009-08-24 Genentech Inc Glycoprotein-sammensætninger
US20040093621A1 (en) 2001-12-25 2004-05-13 Kyowa Hakko Kogyo Co., Ltd Antibody composition which specifically binds to CD20
CA2481920A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. Antibody composition-containing medicament
US20040110704A1 (en) 2002-04-09 2004-06-10 Kyowa Hakko Kogyo Co., Ltd. Cells of which genome is modified
JPWO2003085118A1 (ja) 2002-04-09 2005-08-11 協和醗酵工業株式会社 抗体組成物の製造方法
EP1500698B1 (en) 2002-04-09 2011-03-30 Kyowa Hakko Kirin Co., Ltd. Cell with depression or deletion of the activity of protein participating in gdp-fucose transport
AU2003236019A1 (en) 2002-04-09 2003-10-20 Kyowa Hakko Kirin Co., Ltd. Drug containing antibody composition appropriate for patient suffering from Fc Gamma RIIIa polymorphism
WO2003085119A1 (en) 2002-04-09 2003-10-16 Kyowa Hakko Kogyo Co., Ltd. METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcϜ RECEPTOR IIIa
AU2003239966B9 (en) 2002-06-03 2010-08-26 Genentech, Inc. Synthetic antibody phage libraries
US7361740B2 (en) 2002-10-15 2008-04-22 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004056312A2 (en) 2002-12-16 2004-07-08 Genentech, Inc. Immunoglobulin variants and uses thereof
US20060135403A1 (en) 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
US20050079574A1 (en) 2003-01-16 2005-04-14 Genentech, Inc. Synthetic antibody phage libraries
US7871607B2 (en) 2003-03-05 2011-01-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminoglycanases
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1688439A4 (en) 2003-10-08 2007-12-19 Kyowa Hakko Kogyo Kk COMPOSITION OF CONDENSED PROTEINS
EP1705251A4 (en) 2003-10-09 2009-10-28 Kyowa Hakko Kirin Co Ltd PROCESS FOR PRODUCING ANTIBODY COMPOSITION BY RNA INHIBITION OF FUNCTION OF $ G (A) 1,6-FUCOSYLTRANSFERASE
EA025962B1 (ru) 2003-11-05 2017-02-28 Роше Гликарт Аг АНТИТЕЛА, ОБЛАДАЮЩИЕ ПОВЫШЕННОЙ АФФИННОСТЬЮ К СВЯЗЫВАНИЮ С Fc-РЕЦЕПТОРОМ И ЭФФЕКТОРНОЙ ФУНКЦИЕЙ
JPWO2005053742A1 (ja) 2003-12-04 2007-06-28 協和醗酵工業株式会社 抗体組成物を含有する医薬
RU2386638C2 (ru) 2004-03-31 2010-04-20 Дженентек, Инк. Гуманизированные анти-тфр-бета-антитела
US7785903B2 (en) 2004-04-09 2010-08-31 Genentech, Inc. Variable domain library and uses
PT1737891E (pt) 2004-04-13 2013-04-16 Hoffmann La Roche Anticorpos anti p-selectina
TWI309240B (en) 2004-09-17 2009-05-01 Hoffmann La Roche Anti-ox40l antibodies
ES2579805T3 (es) 2004-09-23 2016-08-16 Genentech, Inc. Anticuerpos y conjugados modificados por ingeniería genética con cisteína
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
EP2465870A1 (en) 2005-11-07 2012-06-20 Genentech, Inc. Binding polypeptides with diversified and consensus VH/VL hypervariable sequences
WO2007064919A2 (en) 2005-12-02 2007-06-07 Genentech, Inc. Binding polypeptides with restricted diversity sequences
WO2007134050A2 (en) 2006-05-09 2007-11-22 Genentech, Inc. Binding polypeptides with optimized scaffolds
EP2059533B1 (en) 2006-08-30 2012-11-14 Genentech, Inc. Multispecific antibodies
GB0624500D0 (en) 2006-12-07 2007-01-17 Istituto Superiore Di Sanito A novel passive vaccine for candida infections
US20080226635A1 (en) 2006-12-22 2008-09-18 Hans Koll Antibodies against insulin-like growth factor I receptor and uses thereof
CN100592373C (zh) 2007-05-25 2010-02-24 群康科技(深圳)有限公司 液晶显示面板驱动装置及其驱动方法
DK2235064T3 (en) 2008-01-07 2016-01-11 Amgen Inc A process for the preparation of heterodimeric Fc molecules using electrostatic control effects
UA107571C2 (xx) 2009-04-03 2015-01-26 Фармацевтична композиція
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
RU2612903C2 (ru) * 2010-08-02 2017-03-13 Ридженерон Фармасьютикалз, Инк. Мыши, у которых вырабатываются связывающие белки, содержащие vl-домены
HUE027649T2 (en) 2010-10-07 2016-10-28 Ac Immune Sa Antibodies recognising phospho-tau
AU2011315181B2 (en) 2010-10-11 2016-07-28 Biogen International Neuroscience Gmbh Human anti-tau antibodies
AU2011349049B2 (en) 2010-12-22 2016-08-11 Teva Pharmaceuticals Australia Pty Ltd Modified antibody with improved half-life
US8703137B2 (en) 2011-01-31 2014-04-22 Intellect Neurosciences Inc. Treatment of tauopathies
GB201112056D0 (en) 2011-07-14 2011-08-31 Univ Leuven Kath Antibodies
WO2013041962A1 (en) 2011-09-19 2013-03-28 Axon Neuroscience Se Protein-based therapy and diagnosis of tau-mediated pathology in alzheimer's disease
ES2600915T3 (es) 2011-10-07 2017-02-13 Ac Immune S.A. Anticuerpos fosfoespecíficos que reconocen Tau
RS59024B1 (sr) 2011-12-20 2019-08-30 Janssen Biotech Inc Anti-phf-tau antitela i njihove upotrebe
AU2013243861A1 (en) * 2012-04-05 2014-10-23 Ac Immune S.A. Humanized Tau antibody
AU2013286680B2 (en) 2012-07-03 2018-07-05 Washington University Antibodies to tau
PL2885010T3 (pl) 2012-08-16 2020-11-16 Ipierian, Inc. Metody leczenia tauopatii
US20140056901A1 (en) 2012-08-21 2014-02-27 The Institute For Molecular Medicine Anti-tau antibodies and compositions for and methods of making and using in treatment, diagnosis and monitoring of tauopathies
EP2887955B1 (en) 2012-08-21 2020-08-19 Institute for Molecular Medicine, Inc. Compositions and methods related to diseases associated with deposits of amyloid, tau, and alpha-synuclein
US9650436B2 (en) * 2012-10-12 2017-05-16 Arizona Board Of Regents On Behalf Of Arizona State University Antibody based reagents that specifically recognize toxic oligomeric forms of tau
MY184251A (en) 2012-12-21 2021-03-29 Biogen Int Neuroscience Gmbh Human anti-tau antibodies
US9259211B2 (en) 2012-12-24 2016-02-16 Transmed7, Llc Automated, selectable, soft tissue excision biopsy devices and methods
US8980270B2 (en) 2013-01-18 2015-03-17 Ipierian, Inc. Methods of treating a tauopathy
EA035943B1 (ru) 2013-03-13 2020-09-03 Протена Биосайенсес Лимитед Антитело, связывающееся с тау-белком человека
WO2014150877A2 (en) * 2013-03-15 2014-09-25 Ac Immune S.A. Anti-tau antibodies and methods of use
CA3173775A1 (en) * 2013-06-10 2014-12-18 Ipierian, Inc. Methods of treating a tauopathy
BR112016010454A2 (pt) 2013-11-27 2017-12-05 Ipierian Inc métodos para tratar uma taupatia
BR112016013562A2 (pt) 2013-12-20 2017-10-03 Hoffmann La Roche Anticorpos anti-tau(ps422) humanizados, seus usos, e formulações farmacêuticas
EP3104870A4 (en) 2014-02-14 2017-09-13 Ipierian, Inc. Tau peptides, anti-tau antibodies, and methods of use thereof
TW202136296A (zh) 2014-06-27 2021-10-01 美商Ｃ２Ｎ醫療診斷有限責任公司 人類化抗-tau抗體
EP3204411A4 (en) 2014-10-10 2018-03-28 National Research Council of Canada Anti-tau antibody and uses thereof
US10323082B2 (en) 2014-10-14 2019-06-18 The Research Foundation For Mental Hygiene, Inc. Treatment of tauopathies by passive immunization targeting the N-terminal projection domain of tau
CA2874083C (en) 2014-12-05 2024-01-02 Universite Laval Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases
EP3261670A4 (en) 2015-02-24 2018-08-01 Rpeptide, LLC Anti-tau antibodies
JO3576B1 (ar) 2015-02-26 2020-07-05 Lilly Co Eli أجسام مضادة لـ tau واستخداماتها
MX392257B (es) 2015-06-05 2025-03-24 Genentech Inc Anticuerpos anti-tau y metodos de uso
EP3307320A4 (en) 2015-06-12 2019-03-06 C2N Diagnostics LLC Stable formulations of humanized anti-tau antibodies
US10344081B2 (en) 2015-07-06 2019-07-09 Ucb Biopharma Sprl Tau-binding antibodies
KR20250027278A (ko) 2015-07-06 2025-02-25 유씨비 바이오파마 에스알엘 타우 결합 항체
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
US20190224339A1 (en) 2016-04-29 2019-07-25 Voyager Therapeutics, Inc. Compositions for the treatment of disease
BR112018072389A2 (pt) 2016-05-02 2019-02-19 Prothena Biosciences Limited anticorpos que reconhecem tau
JP7029415B2 (ja) 2016-07-12 2022-03-03 ハー・ルンドベック・アクチエゼルスカベット 過リン酸化タウに特異的な抗体およびその使用方法
EP3551655A2 (en) 2016-12-07 2019-10-16 Genentech, Inc. Anti-tau antibodies and methods of their use
CN118165104A (zh) 2016-12-07 2024-06-11 基因泰克公司 抗tau抗体和使用方法
TWI848907B (zh) 2017-03-28 2024-07-21 美商建南德克公司 治療神經退化性疾病之方法

Also Published As

Publication number Publication date
RU2017145540A (ru) 2019-07-16
ZA201707644B (en) 2020-01-29
IL300670B1 (en) 2024-10-01
CN107849124A (zh) 2018-03-27
JP7403429B2 (ja) 2023-12-22
CR20180013A (es) 2018-12-06
IL300670A (en) 2023-04-01
MX392257B (es) 2025-03-24
TW202428606A (zh) 2024-07-16
EP4465050A2 (en) 2024-11-20
TW201713687A (zh) 2017-04-16
KR102768863B1 (ko) 2025-02-18
TW202313676A (zh) 2023-04-01
PL3303386T3 (pl) 2025-03-03
DK3303386T3 (da) 2024-10-28
IL255578A (en) 2018-01-31
RU2017145540A3 (es) 2020-01-28
IL300670B2 (en) 2025-02-01
JP2018519810A (ja) 2018-07-26
IL314569A (en) 2024-09-01
US11555065B2 (en) 2023-01-17
UA126272C2 (uk) 2022-09-14
CN107849124B (zh) 2021-09-24
TWI730963B (zh) 2021-06-21
TWI790642B (zh) 2023-01-21
ZA201907054B (en) 2022-03-30
CL2019003114A1 (es) 2020-06-19
SI3303386T1 (sl) 2025-03-31
SG10201911349YA (en) 2020-01-30
EP3303386A1 (en) 2018-04-11
AR104875A1 (es) 2017-08-23
TW202212356A (zh) 2022-04-01
ES2991587T3 (es) 2024-12-03
MA44955A (fr) 2019-03-20
ZA202107931B (en) 2023-10-25
US20240067707A1 (en) 2024-02-29
PH12021551770A1 (en) 2022-09-05
WO2016196726A1 (en) 2016-12-08
FI3303386T3 (fi) 2024-11-13
CA2986942C (en) 2025-07-22
CO2018000046A2 (es) 2018-03-28
US20190112361A1 (en) 2019-04-18
JP2021048845A (ja) 2021-04-01
NZ737796A (en) 2025-02-28
CL2017003063A1 (es) 2018-03-09
US10633436B2 (en) 2020-04-28
EP4465050A3 (en) 2025-06-11
PH12017502165A1 (en) 2018-06-04
US20190367591A1 (en) 2019-12-05
IL255578B1 (en) 2023-03-01
KR20180014764A (ko) 2018-02-09
HK1249531A1 (zh) 2018-11-02
JP2023179407A (ja) 2023-12-19
US10112990B2 (en) 2018-10-30
CA3258972A1 (en) 2025-04-17
JP6793134B2 (ja) 2020-12-02
AU2022209213A1 (en) 2022-09-15
US20210332114A1 (en) 2021-10-28
CA2986942A1 (en) 2016-12-08
US20190112362A1 (en) 2019-04-18
WO2016196726A9 (en) 2017-04-13
MX2022003272A (es) 2022-04-11
AU2016270858B2 (en) 2022-04-28
MX2022003273A (es) 2022-04-11
AU2016270858A1 (en) 2018-01-18
US10329344B2 (en) 2019-06-25
US10336819B2 (en) 2019-07-02
IL255578B2 (en) 2023-07-01
PT3303386T (pt) 2024-11-12
CN114057872A (zh) 2022-02-18
TWI827405B (zh) 2023-12-21
RU2732122C2 (ru) 2020-09-11
MX2017015464A (es) 2018-03-28
US20160376351A1 (en) 2016-12-29
EP3303386B1 (en) 2024-08-28
NZ775762A (en) 2025-02-28

Similar Documents

Publication Publication Date Title
PE20180317A1 (es) Anticuerpos anti-tau y metodos de uso
MY198942A (en) Anti-tau antibodies and methods of use
BR112017009817A2 (pt) anticorpos anti-il-1beta e métodos de utilização
ES2685424T3 (es) Anticuerpos anti-Jagged1 y procedimientos de uso
AR102918A1 (es) Anticuerpos anti-cd79b y métodos de uso
MX2017005642A (es) Anticuerpos anti-angiopoyetina 2 (ang2) y metodos de uso.
AR096687A1 (es) Anticuerpos anti-fcrh5
ZA201804654B (en) Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
PE20161571A1 (es) Anticuerpos anti-ox40 y metodos de uso
PE20181336A1 (es) Anticuerpos que se unen a interleucina 8 (il-8) y sus usos
AR099855A1 (es) Anticuerpos hemaglutinina del virus antiinfluenza b y métodos de uso
MX387662B (es) Anticuerpos humanizados anti grupo de diferenciacion 19 (cd19) humano y metodos de uso.
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
EA201792413A1 (ru) Антитела против cd71, активируемые антитела против cd71 и способы их применения
EA201990071A1 (ru) Композиция пептидной вакцины
PE20141693A1 (es) Metodos para tratar el cancer por el uso de antagonistas de union al eje pd-1e inhibidores de mek
EA201792414A1 (ru) Антитела против cd166, активируемые антитела против cd166 и способы их применения
AR105026A1 (es) ANTICUERPOS MADURADOS POR AFINIDAD Y HUMANIZADOS PARA FcRH5 Y MÉTODOS PARA SU USO
WO2015143123A3 (en) Antibodies against immunogenic glycopeptides, composition comprising the same and use thereof
AR107077A1 (es) Anticuerpos anti-c5 y métodos para su uso
PE20210629A1 (es) Anticuerpos anti-klk5 y metodos de uso
AR078377A1 (es) Anticuerpos anti-vegf-c (factor de crecimiento endotelial anti-vascular aislado c) y sus metodos de uso
WO2015107363A3 (en) Mycobacterial antigen composition
RU2018130986A (ru) Антитела к jagged и способы их применения